Abstract:Monoclonal antibodies (mAb) are commonly manufactured by either discontinuous operations like fed-batch (FB) or continuous processes such as steady-state perfusion. Both process types comprise opposing advantages and disadvantages in areas such as plant utilization, feasible cell densities, media consumption and process monitoring effort. In this study, we show feasibility of a promising novel hybrid process strategy that combines beneficial attributes of both process formats. In detail, our strategy comprises a short duration FB, followed by a fast media exchange and cell density readjustment, marking the start of the next FB cycle. Utilizing a small-scale screening tool, we were able to identify beneficial process parameters, including FB interval duration and reinoculation cell density, that allow for multiple cycles of the outlined process in a reproducible manner. In addition, we could demonstrate scalability of the process to a 5L benchtop system, using a fluidized-bed centrifuge as scalable media exchange system. The novel process showed increased productivity (+217%) as well as longer cultivation duration, in comparison to a standard FB with a significantly lower media consumption per produced product (-50%) and a decreased need for process monitoring, in comparison to a perfusion cultivation. Further, the process revealed constant glycosylation pattern in comparison to the perfusion cultivation and has strong potential for further scale-up, due to the use of fully scalable cultivation and media exchange platforms. In summary, we have developed a novel hybrid process strategy that tackles the key challenges of current biomanufacturing of either low productivity or high media consumption, representing a new and innovative approach for future process intensification efforts.

Methods and strategies available for the process control and optimization of monoclonal antibody production

Chromatographic technology in antibody purification and its progress

Analysis and Optimal Design of Batch and Two‐column Continuous Chromatographic Frontal Processes for Monoclonal Antibody Purification

Model-assisted process development, characterization and design of continuous chromatography for antibody separation

Model-Based Optimization of a Fed-Batch Bioreactor for mAb Production Using a Hybridoma Cell Culture

Improved Control Strategies for the Environment Within Cell Culture Bioreactors

Recent Advances in Cell Engineering for Monoclonal Antibody Production

Dynamic optimization of an integrated cultivation‐aggregation model for mAb production

Chemometric Identification of Canonical Metabolites Linking Critical Process Parameters to Monoclonal Antibody Production During Bioprocess Development

Optimization of the Process of Chinese Hamster Ovary (CHO) Cell Fed-Batch Culture to Stabilize Monoclonal Antibody Production and Overall Quality: Effect of pH Control Strategies

Dynamic Optimization for Monoclonal Antibody Production

Fed-Batch Culture Of Hybridoma Cells In Serum-Free Medium Using An Optimized Feeding Strategy

Recent advances in technology supporting biopharmaceutical production from mammalian cells

A novel hybrid bioprocess strategy addressing key challenges of advanced biomanufacturing

Bioprocessing of mAb (Monoclonal Antibodies) using Chinese Hamster Ovary (CHO) Cells: A Review

From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies

Population balance modelling captures host cell protein dynamics in CHO cell cultures

Developing the biofacility of the future based on continuous processing and single-use technology

Exploring the limits of conventional small-scale CHO fed-batch for accelerated on demand monoclonal antibody production

Towards advanced bioprocess optimization: A multiscale modelling approach

Optimization of Protein Expression in Mammalian Cells